DCC-2036 (Rebastinib)
DCC-2036 is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity.
Important Notice: For research use only. We do not sell to patients.
Loading distributor info...
DCC-2036 is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity.
Important Notice: For research use only. We do not sell to patients.
Loading distributor info...
Discription | DCC-2036 is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. |
||
---|---|---|---|
Targets |
|
Catalog Num | A11200 |
---|---|
Formula | C30H28FN7O3 |
Molecular Weight | 553.59 |
CAS Number | 1020172-07-9 |
SMILES | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 |
Synonyms | DCC2036 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
In vitro (25°C) | DMSO | 103 mg/mL (186.05 mM) | |
Water | Insoluble | ||
Ethanol | 15 mg/mL (27.09 mM) | ||
In vivo | 0.5% CMC+0.25% Tween 80 | 15 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.06 mL | 90.32 mL | 180.64 mL |
0.5 mM | 3.61 mL | 18.06 mL | 36.13 mL |
1 mM | 1.81 mL | 9.03 mL | 18.06 mL |
5 mM | 0.36 mL | 1.81 mL | 3.61 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2